These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2476502)

  • 1. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement.
    Okada N; Harada R; Fujita T; Okada H
    J Immunol; 1989 Oct; 143(7):2262-6. PubMed ID: 2476502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes.
    Harada R; Okada N; Fujita T; Okada H
    J Immunol; 1990 Mar; 144(5):1823-8. PubMed ID: 2307842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes.
    Okada H; Tanaka H; Okada N
    Eur J Immunol; 1983 Apr; 13(4):340-4. PubMed ID: 6221932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A monoclonal antibody that blocks the complement regulatory activity of guinea pig erythrocytes and characterization of the antigen involved as guinea pig decay-accelerating factor.
    Okada N; Tanaka H; Takizawa H; Okada H
    J Immunol; 1995 Jun; 154(11):6103-11. PubMed ID: 7538542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ability to activate the alternative complement pathway acquired by human and guinea-pig erythrocytes after contact with influenza virus.
    Lambré C; Thibon M
    Ann Immunol (Paris); 1980; 131C(2):213-21. PubMed ID: 7416718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of a 35-kilodalton purified protein from Loxosceles intermedia spider venom transforms human erythrocytes into activators of autologous complement alternative pathway.
    Tambourgi DV; Magnoli FC; Von Eickstedt VR; Benedetti ZC; Petricevich VL; da Silva WD
    J Immunol; 1995 Nov; 155(9):4459-66. PubMed ID: 7594608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement.
    Okada N; Harada R; Fujita T; Okada H
    Int Immunol; 1989; 1(2):205-8. PubMed ID: 2487685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for restriction of the ability of complement to lyse homologous erythrocytes.
    Houle JJ; Hoffmann EM
    J Immunol; 1984 Sep; 133(3):1444-52. PubMed ID: 6430999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the human classical complement pathway by a mouse monoclonal hybrid IgG1-2a monovalent anti-TNP antibody bound to TNP-conjugated cells.
    Couderc J; Kazatchkine MD; Ventura M; Duc HT; Maillet F; Thobie N; Liacopoulos P
    J Immunol; 1985 Jan; 134(1):486-91. PubMed ID: 3917282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor.
    Pearce EJ; Hall BF; Sher A
    J Immunol; 1990 Apr; 144(7):2751-6. PubMed ID: 1690776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
    Deng J; Gold D; LoVerde PT; Fishelson Z
    Int J Parasitol; 2007 Jan; 37(1):67-75. PubMed ID: 17123534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
    Moore FD; Austen KF; Fearon DT
    J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterotoxicity of human serum. IV. Role of the alternative complement pathway and natural antibody in the lethal toxicity of human serum for mice.
    Rozenfarb E; Eidinger D
    Int Arch Allergy Appl Immunol; 1979; 60(4):414-26. PubMed ID: 500231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A sensitive microassay for the murine alternative complement pathway.
    Joiner KA; Shahon R; Gelfand JA
    J Immunol Methods; 1979; 31(3-4):283-90. PubMed ID: 521632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement inhibitor of rat cell membrane resembling mouse Crry/p65.
    Takizawa H; Okada N; Okada H
    J Immunol; 1994 Mar; 152(6):3032-8. PubMed ID: 8144902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of surface modulations by enzymes and monoclonal antibodies on alternative complement pathway activation by Yersinia enterocolitica.
    Wachter E; Brade V
    Infect Immun; 1989 Jul; 57(7):1984-9. PubMed ID: 2731980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate.
    Sher A; Hieny S; Joiner K
    J Immunol; 1986 Nov; 137(9):2961-7. PubMed ID: 3531342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different functions for specific guinea pig IgG1 and IgG2 in the lysis of sheep erythrocytes by C4-deficient guinea pig serum.
    Nicholson-Weller A; Daha MR; Austen KF
    J Immunol; 1981 May; 126(5):1800-4. PubMed ID: 7217667
    [No Abstract]   [Full Text] [Related]  

  • 19. IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b.
    Moore FD; Fearon DT; Austen KF
    J Immunol; 1981 May; 126(5):1805-9. PubMed ID: 6908606
    [No Abstract]   [Full Text] [Related]  

  • 20. Relative inefficiency of terminal complement activation.
    Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
    J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.